Iconix Provides Chemogenomic Profiling Services to AstraZeneca

Jun 02, 2004

NEW YORK, June 2 (GenomeWeb News) - Iconix Pharmaceuticals will provide chemogenomic profiling services for AstraZeneca, the company said today.

Under the agreement, Mountain View, Calif.-based Iconix will profile compounds from AstraZeneca for toxicity using its Drug Signatures library, a collection of predictive biomarkers derived from its chemogenomics reference database.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Sharing, But Kinda Sorta

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

This Week in Science

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

Structural Biologist Leads India's CSIR

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

Upward of One Hundred

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

Main menu